We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity

J Am Coll Cardiol. 2011 Jul 5;58(2):198; author reply 198-9. doi: 10.1016/j.jacc.2011.02.048.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Administration, Oral
  • Alleles
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Asian People
  • Blood Platelets / metabolism
  • Cilostazol
  • Clinical Trials as Topic
  • Coronary Disease / genetics
  • Coronary Disease / therapy
  • Cytochrome P-450 CYP2C19
  • Drug-Eluting Stents
  • Ethnicity
  • Genotype
  • Humans
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Count
  • Prevalence
  • Research Design
  • Tetrazoles / pharmacology*
  • Thrombosis / genetics
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Tetrazoles
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Cilostazol